NBY

Company Overview — What Does NovaBay Pharmaceuticals, Inc. Do?

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. NovaBay Pharmaceuticals, Inc. (NBY) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Justin M. Hall and employs approximately 30 people, headquartered in Emeryville, California. With a market capitalization of $42M, NBY is one of the notable companies in the Healthcare sector.

NovaBay Pharmaceuticals, Inc. (NBY) Stock Rating — Reduce (April 2026)

As of April 2026, NovaBay Pharmaceuticals, Inc. receives a Reduce rating with a composite score of 31.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NBY ranks #3,395 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, NovaBay Pharmaceuticals, Inc. ranks #518 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NBY Stock Price and 52-Week Range

NovaBay Pharmaceuticals, Inc. (NBY) currently trades at $1.28. The stock lost $0.08 (5.9%) in the most recent trading session. The 52-week high for NBY is $19.95, which means the stock is currently trading -93.6% from its annual peak. The 52-week low is $0.43, putting the stock 194.8% above its annual trough. Recent trading volume was 226K shares, suggesting relatively thin trading activity.

Is NBY Overvalued or Undervalued? — Valuation Analysis

NovaBay Pharmaceuticals, Inc. (NBY) carries a value factor score of 18/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 16.01x, compared to the Healthcare sector average of 23.63x — a discount of 32%. The price-to-book ratio stands at 29.92x, versus the sector average of 2.75x. The price-to-sales ratio is 17.53x, compared to 1.66x for the average Healthcare stock.

At current multiples, NovaBay Pharmaceuticals, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

NovaBay Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

NovaBay Pharmaceuticals, Inc. (NBY) earns a quality factor score of 11/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 292.4%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 35.9% versus the sector average of -33.1%.

On a margin basis, NovaBay Pharmaceuticals, Inc. reports gross margins of 36.7%, compared to 71.5% for the sector. The operating margin is -142.3% (sector: -66.1%). Net profit margin stands at -148.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -78.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NBY Debt, Balance Sheet, and Financial Health

NovaBay Pharmaceuticals, Inc. has a debt-to-equity ratio of 167.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 7.60x, indicating strong short-term liquidity. Total debt on the balance sheet is $149,000. Cash and equivalents stand at $2M.

NBY has a beta of 0.62, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for NovaBay Pharmaceuticals, Inc. is 24/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

NovaBay Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, NovaBay Pharmaceuticals, Inc. reported revenue of $3M and earnings per share (EPS) of $-3.80. Net income for the quarter was $3M. Gross margin was 36.7%. Operating income came in at $-7M.

In FY 2025, NovaBay Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.80. Net income for the quarter was $-22M. Operating income came in at $-8M.

In Q3 2025, NovaBay Pharmaceuticals, Inc. reported revenue of $521,000 and earnings per share (EPS) of $-0.22. Net income for the quarter was $-1M. Gross margin was 8.1%. Revenue grew -78.7% year-over-year compared to Q3 2024. Operating income came in at $-1M.

In Q2 2025, NovaBay Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.33. Net income for the quarter was $-2M. Operating income came in at $-2M.

Over the past 8 quarters, NovaBay Pharmaceuticals, Inc. has demonstrated a growth trajectory, with revenue expanding from $2M to $3M. Investors analyzing NBY stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NBY Dividend Yield and Income Analysis

NovaBay Pharmaceuticals, Inc. (NBY) currently pays a dividend yield of 62.5%. At this yield, a $10,000 investment in NBY stock would generate approximately $$6250.00 in annual dividend income.

NBY Momentum and Technical Analysis Profile

NovaBay Pharmaceuticals, Inc. (NBY) has a momentum factor score of 50/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 66/100 reflects moderate short selling activity.

NBY vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, NovaBay Pharmaceuticals, Inc. (NBY) ranks #518 out of 838 stocks based on the Blank Capital composite score. This places NBY in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing NBY against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NBY vs S&P 500 (SPY) comparison to assess how NovaBay Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

NBY Next Earnings Date

No upcoming earnings date has been announced for NovaBay Pharmaceuticals, Inc. (NBY) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NBY? — Investment Thesis Summary

The quantitative profile for NovaBay Pharmaceuticals, Inc. suggests caution. The quality score of 11/100 flags below-average profitability. The value score of 18/100 indicates premium valuation. High volatility (stability score 24/100) increases portfolio risk.

In summary, NovaBay Pharmaceuticals, Inc. (NBY) earns a Reduce rating with a composite score of 31.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NBY stock.

Related Resources for NBY Investors

Explore more research and tools: NBY vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NBY head-to-head with peers: NBY vs AZN, NBY vs SLGL, NBY vs VMD.